One Blood Test. Fifty Cancers. The Screening Revolution That Could Save Millions of Lives.
A cardiologist explains the science behind the Galleri test, why the FDA could approve it this year, and what it means for the future of cancer — and heart disease.
I have spent twenty years as a cardiologist watching patients survive heart attacks, optimize their metabolic health, clean up their arteries, transform their labs — and then receive a late-stage cancer diagnosis that nobody screened for because no screening tool existed.
I have stood in hospital rooms and delivered the news that a patient’s pancreatic cancer was Stage 4. That the window for curative treatment had closed. That the disease I spent two decades learning to fight — heart disease — had been beaten, only for a different disease to arrive unannounced and win.
Those moments haunt me. Because in almost every case, the cancer was growing silently for years before anyone knew. Not because medicine didn’t have treatments. But because medicine didn’t look.
We didn’t look because we didn’t have a way to look.
That may be about to change.
NPR reported on June 22, 2026 — today — on a blood test that could transform cancer screening more fundamentally than anything in a generation. It’s called Galleri, it’s made by a company called GRAIL, and the FDA could approve it later this year.
One vial of blood. One test. Screening for up to fifty different cancers at once.
This is the story of how it works, what the data shows, where it stands, and why — as a cardiologist who has written extensively about the convergence of metabolic health, inflammation, and disease — I believe this could be the most important diagnostic tool of the decade.
The Problem: We Screen for Five Cancers. The Other Forty-Five Kill in Silence.
Right now, in the United States, we have routine screening programs for exactly five cancers: breast (mammography), colon (colonoscopy), cervical (Pap smear/HPV test), prostate (PSA, debated), and lung (low-dose CT for high-risk smokers).
Each requires its own separate scan, procedure, or exam. Each catches one cancer type. Together, these five represent a fraction of the more than 200 types of cancer that exist.
For the rest — pancreatic cancer, ovarian cancer, liver cancer, esophageal cancer, gastric cancer, bile duct cancer, and dozens more — we have no population-level screening at all. We find them when patients develop symptoms. And by the time symptoms appear, the vast majority are Stage 3 or 4.
The survival statistics tell the story of what late detection means.
Pancreatic cancer: 12% five-year survival. Ovarian cancer: 50%. Liver cancer: 21%. Esophageal cancer: 22%. Gastric cancer: 36%.
These numbers are not treatment failures. The treatments, in many cases, exist and are improving rapidly — immunotherapy, targeted therapy, personalized mRNA vaccines, surgical advances. The failure is detection. We find the disease after the window for effective treatment has closed.
Cancer is now the number one killer of Americans over the age of 50. Not heart disease. Cancer. And the reason it kills so many isn’t that we can’t fight it. It’s that we don’t see it coming.
Galleri is designed to change that equation.
How It Works: Your Blood as a Window into Every Organ
The science behind Galleri is called liquid biopsy — and it represents one of the most elegant applications of genomics and artificial intelligence in modern medicine.
Here is the core insight: every tumor in your body, no matter where it’s located, constantly sheds material into your bloodstream. As cancer cells die, divide, and grow, they release tiny fragments of their DNA — called circulating tumor DNA, or ctDNA — into the blood. These fragments are mixed in with the vastly larger pool of DNA released by your healthy cells.
The challenge has always been distinguishing the cancer signal from the noise of normal cell-free DNA. Galleri solves this through a technology called methylation analysis.
Every cell in your body contains the same DNA sequence. What makes a liver cell different from a brain cell different from a skin cell is epigenetics — the chemical modifications that tell genes when to turn on and off. The most important of these modifications is methylation: the attachment of methyl groups to specific locations on the DNA strand.
Cancer cells have profoundly abnormal methylation patterns. Their epigenetic code is corrupted in ways that are distinct from healthy tissue — and, critically, distinct in ways that are specific to the type of cancer and the organ it originated in.
Galleri captures cell-free DNA from a standard blood draw — a single vial — and sequences the methylation patterns across the genome using next-generation sequencing. An AI algorithm trained on massive datasets then analyzes these patterns to determine two things:
First, whether a cancer signal is present at all.
Second, where it’s likely coming from — which organ or tissue type is the probable source. This is called cancer signal origin prediction, and in studies, Galleri has achieved over 90% accuracy in identifying the tissue of origin.
The test result is not a diagnosis. It is a precision compass. It tells your physician: there is a cancer signal detected, and the predicted origin is your pancreas, or your lung, or your liver. Your physician then orders targeted follow-up imaging or biopsy to confirm or rule out the finding.
Think of it this way: your bloodstream is a river that flows past every organ in your body. Every tumor upstream is leaking evidence into that river — DNA fragments with unique chemical fingerprints. Galleri scoops a cup of water from the river, reads the fingerprints, and tells your doctor which factory upstream is the source.
One blood draw. Fifty cancers. A map to tell your doctor exactly where to look next.
The Data: What the Largest Studies in History Show
Galleri isn’t a concept or a prototype. Over 475,000 tests have been sold commercially in the United States under a special FDA designation. Two landmark studies form the backbone of the FDA application submitted in January 2026.
The NHS-Galleri Trial is the largest randomized controlled trial of any multi-cancer detection test in history. Over 142,000 asymptomatic participants aged 50 to 77 were enrolled across England through the National Health Service.
The primary endpoint — an overall statistically significant reduction in the incidence of Stage 3 and 4 cancers — was not met. I want to be transparent about that because honesty about data limitations is what separates science from marketing.
But the secondary findings are striking. By the third year of annual screening, the study found a 26% reduction in Stage IV cancers in key deadly types — pancreatic, liver, lung, and gastric cancer. The test detected four times more cancers overall when added to standard screening, catching cancers at earlier, more treatable stages that would otherwise have been found late or through emergency presentations.
GRAIL’s VP of medical affairs, Megan Hall, noted: “The treatment landscape has evolved so much over the past five to ten years that there are now a lot of treatments even for Stage 3. Catching cancer at Stage 3 versus Stage 4 has never been more significant for survival.”
The Pathfinder 2 Study enrolled 25,490 participants in the United States — adults over 50 with no symptoms and no clinical suspicion of cancer. The study examined the safety and accuracy of Galleri when added alongside standard screening. The results form the primary basis of the FDA submission.
The combined data from both studies, presented at the 2026 American Society of Clinical Oncology annual meeting, show a consistent and promising pattern: Galleri, when added to existing screening, catches cancers that current screening misses — particularly the deadly cancers for which no screening currently exists.
The Regulatory Path: FDA Decision Expected This Year
GRAIL submitted the final module of its Premarket Approval (PMA) application to the FDA on January 29, 2026. The test has held Breakthrough Device designation since 2018 — a designation reserved for technologies that address unmet medical needs with the potential for substantial clinical improvement.
Many industry observers expect an FDA decision later this year.
Congress has already acted in anticipation. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act passed in February 2026 as part of a larger spending package. The legislation allows Medicare to reimburse the cost of FDA-approved multi-cancer detection tests starting in 2028 — one test per year, with age-based phasing.
The current retail price for Galleri is approximately $950. Exact Sciences’ competing test, Cancerguard, is $659. These prices will fall significantly once FDA approval triggers commercial insurance coverage and competition drives the market.
Arif Kamal, chief patient officer at the American Cancer Society, said the science is sound and the technology solid — the only question is how quickly it evolves. He called the potential for simpler, more accessible routine screening a paradigm shift.
The Competition: A New Category of Medicine
Galleri is not alone. An entire industry is emerging around multi-cancer early detection.
Exact Sciences’ Cancerguard launched as a laboratory-developed test in September 2025. Abbott is acquiring Exact Sciences for $21 billion — a signal of how seriously the pharmaceutical industry takes this category.
Guardant Health’s Shield test, originally developed for colorectal cancer screening, now offers physicians the option to receive multi-cancer results.
Hundreds of companies are pursuing liquid biopsy approaches — competing over sensitivity, specificity, cost, and clinical utility. The technology is advancing rapidly. Newer versions are integrating proteomics (protein analysis), fragmentomics (the size and pattern of DNA fragments), and multi-omics approaches that combine multiple data streams for even greater accuracy.
UCLA lung cancer specialist Jonathan Goldman told NPR: “Blood-based testing has become central to the way we think about lung cancer and other cancers because the systems have become so sensitive.” He added that the future may include blood tests sensitive enough to detect cells at risk of becoming cancerous years before a tumor forms.
We are watching the birth of a new category of medicine: proactive, multi-cancer, blood-based screening that could make comprehensive cancer detection as routine as a cholesterol panel.
The Limitations: What Galleri Cannot Do
I am a physician. I owe you the limitations as much as the promise.
Galleri is not a diagnostic tool. A positive result does not mean you have cancer. It means a cancer signal was detected and further evaluation is needed. A negative result does not guarantee you are cancer-free — some cancers, particularly very early-stage tumors, may shed too little DNA to be detected.
Sensitivity for Stage 1 cancers is lower than for later stages. This is inherent to the biology — very small tumors release very little material into the bloodstream. The test is better at detecting the cancers most likely to kill you (aggressive, later-stage) than the ones least likely to (slow-growing, early-stage).
False positives can occur. A cancer signal detected result that turns out to be negative on follow-up creates anxiety, additional testing, and cost. Managing the psychological and clinical impact of false positives will be an important part of implementing this technology responsibly.
Not all cancers shed equally into the blood. Brain tumors, for example, are harder to detect because the blood-brain barrier limits DNA release into systemic circulation.
The NHS-Galleri trial did not meet its primary endpoint. The trend data is promising, but the definitive proof that annual multi-cancer screening reduces cancer mortality at a population level has not yet been established. That evidence will come from continued follow-up and future trials.
And the privacy implications of population-scale cancer screening — generating detailed molecular data on millions of people — deserve serious public conversation.
These limitations are real. They do not diminish the breakthrough. They define the boundaries within which we must implement it responsibly.
Why This Matters to a Cardiologist
I’ve spent months on this platform and in this newsletter writing about a single theme: the convergence of metabolic health, inflammation, and disease.
GLP-1 drugs reducing cancer metastasis by up to 50% — because the same metabolic dysfunction driving heart disease fuels cancer progression.
Personalized mRNA cancer vaccines cutting recurrence by 49% — because the immune system, properly trained, can hunt cancer with precision no chemotherapy can match.
AI detecting inflamed arteries years before a heart attack — because the technology to see inside the body is advancing faster than our clinical practice has caught up to.
Gene editing permanently lowering cholesterol with a single injection — because we are shifting from managing disease to correcting the code that causes it.
Galleri connects all of it.
Detect the cancer early — with a simple blood test. Confirm the location with AI-enhanced imaging. Treat it with personalized vaccines, targeted therapy, immunotherapy, and GLP-1 drugs that may slow progression. Monitor response in real time with serial liquid biopsies.
That’s not five separate advances. It’s one integrated system of cancer prevention and treatment that didn’t exist five years ago — and could be standard of care within five more.
The shift from reactive to proactive medicine — from “we found it too late” to “we caught it in time” — is the defining story of this decade in medicine. I see it in cardiology. I see it in oncology. I see it in neurology, in metabolic medicine, in the emerging science of aging itself.
Galleri is the screening tool that makes the rest possible. Because none of these extraordinary treatments matter if we don’t find the disease early enough to use them.
What You Can Do Right Now
If you are over 50, or have a family history of cancer, or carry known risk factors — here is what I’d tell you as your physician.
Ask your doctor about the Galleri test. It is currently available as a laboratory-developed test that can be ordered by a physician. The cost is approximately $950 out of pocket. Some concierge and longevity medicine practices already offer it.
Do not replace your existing screening. Galleri is designed to complement — not substitute for — mammograms, colonoscopies, Pap smears, and lung CT screening. The legislation that will allow Medicare coverage explicitly specifies this. Think of it as an additional layer of protection for the cancers your current screening doesn’t cover.
Know your metabolic health. The same insulin resistance, chronic inflammation, and metabolic dysfunction that drive heart disease also create the environment in which cancers grow and spread. Get your ApoB, Lp(a), hsCRP, fasting insulin, and vitamin D tested. Optimize your metabolic foundation — because cancer prevention and cardiovascular prevention share the same roots.
Watch for the FDA decision. If Galleri receives full FDA approval later this year, it will trigger commercial insurance coverage negotiations and, by 2028, Medicare reimbursement. The cost barrier that currently limits access will begin to fall.
Stay informed about the competition. Cancerguard by Exact Sciences, Shield by Guardant Health, and dozens of emerging tests are advancing rapidly. The market dynamics of competition will drive prices down, sensitivity up, and accessibility outward.
The Bottom Line
Cancer kills more Americans over 50 than any other cause. Not because we can’t treat it. Because we find it too late.
For decades, the screening paradigm has been fragmented — one test per cancer, each requiring its own scan or procedure, covering only a handful of the hundreds of cancer types that exist. The deadliest cancers — pancreatic, ovarian, liver, esophageal — have had no routine screening at all.
Galleri represents a fundamental shift: from reactive, single-cancer screening to proactive, multi-cancer early detection using one simple blood test.
The science is real — built on genomics, methylation analysis, and AI. The studies are the largest in history. The FDA submission is filed. Congress has already cleared the path for Medicare coverage. And the competitive landscape ensures that this technology will only get more sensitive, more accurate, and more affordable with time.
We are watching the same paradigm shift in oncology that I’ve been writing about in cardiology: the transition from managing disease after it arrives to detecting and preventing it before it takes hold.
Prevention is the new cure. And one vial of blood may be the most powerful tool we’ve ever had to make that real.
If this article resonated with you, please share it with someone who needs to read it. The more people who know about multi-cancer early detection, the faster the clinical adoption, the faster the insurance coverage, and the more lives saved.
And if you haven’t already — ask your doctor. The test exists. Today.
Blessings.
Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine
Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)
Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile
This is a clear explainer, and stating plainly that the primary endpoint was missed is rarer than it should be in writing about this test.
The limitation you list may be its best property. If shedding scales with how aggressive a tumor is, then the cancers Galleri detects poorly are largely the indolent ones that were never going to kill the patient, and the ones it detects well are the ones that were. Screening programs have historically had the opposite bias. Low Stage 1 sensitivity looks like a weakness until you ask which Stage 1 tumors are being missed.
I appreciate the article and find it interesting there is no disclosure of Dr. Emrani's possible association with this test or any other.